JP2016536005A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536005A5
JP2016536005A5 JP2016543983A JP2016543983A JP2016536005A5 JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5 JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5
Authority
JP
Japan
Prior art keywords
cell population
test cell
mitochondrial
contacting
outer membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536005A (ja
JP6663852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/056284 external-priority patent/WO2015042249A1/en
Publication of JP2016536005A publication Critical patent/JP2016536005A/ja
Publication of JP2016536005A5 publication Critical patent/JP2016536005A5/ja
Application granted granted Critical
Publication of JP6663852B2 publication Critical patent/JP6663852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543983A 2013-09-19 2014-09-18 Bh3プロファイリングの方法 Active JP6663852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879869P 2013-09-19 2013-09-19
US61/879,869 2013-09-19
PCT/US2014/056284 WO2015042249A1 (en) 2013-09-19 2014-09-18 Methods of bh3 profiling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019188457A Division JP2020012850A (ja) 2013-09-19 2019-10-15 Bh3プロファイリングの方法

Publications (3)

Publication Number Publication Date
JP2016536005A JP2016536005A (ja) 2016-11-24
JP2016536005A5 true JP2016536005A5 (enExample) 2017-11-02
JP6663852B2 JP6663852B2 (ja) 2020-03-13

Family

ID=52689380

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016543983A Active JP6663852B2 (ja) 2013-09-19 2014-09-18 Bh3プロファイリングの方法
JP2019188457A Withdrawn JP2020012850A (ja) 2013-09-19 2019-10-15 Bh3プロファイリングの方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019188457A Withdrawn JP2020012850A (ja) 2013-09-19 2019-10-15 Bh3プロファイリングの方法

Country Status (6)

Country Link
US (2) US10739333B2 (enExample)
EP (1) EP3047276B1 (enExample)
JP (2) JP6663852B2 (enExample)
AU (1) AU2014323526B2 (enExample)
CA (1) CA2922503C (enExample)
WO (1) WO2015042249A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016255749B2 (en) * 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU705563B2 (en) 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
WO1997015831A1 (en) 1995-10-24 1997-05-01 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2001012661A2 (en) 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
EP1455819A1 (en) 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1608969A4 (en) 2003-03-19 2007-06-06 Alfa Wassermann Inc SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) * 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
US20070027175A1 (en) * 2005-07-27 2007-02-01 Shaughnessy John Jr Antineoplastic activities of ellipticine and its derivatives
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) * 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) 2006-07-07 2007-12-18 김현기 Hccr-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
CA2699794C (en) * 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
MX2011013385A (es) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2010147961A1 (en) * 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
WO2013170176A2 (en) 2012-05-10 2013-11-14 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
WO2013188978A1 (en) 2012-06-20 2013-12-27 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
WO2014047342A1 (en) * 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
AU2014323526B2 (en) * 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
AU2016255749B2 (en) 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING

Similar Documents

Publication Publication Date Title
JP2015531606A5 (enExample)
CY1123747T1 (el) Χιμαιρικα μορια τελεστες με σημανση και υποδοχεις αυτων
MX391457B (es) Sistema y metodo para matriz de sensores de corona de proteinas para la deteccion temprana de enfermedades.
JP2020012850A5 (enExample)
CY1121741T1 (el) Χρηση του μεγεθους θραυσματων εξωκυτταριου dna για τον προσδιορισμο παραλλαγης αριθμου αντιγραφων
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
TR201900160T4 (tr) Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler.
MX392706B (es) Ensayo a base de células para detectar homodímeros anti-cd3.
JP2018514210A5 (enExample)
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX2020003523A (es) Deteccion de dimetilarginina simetrica.
MX2017006831A (es) Sistemas y metodos para la determinacion electroquimica de hematocrito mediante determinaciones de angulos de fase de impedancia de corriente alterna.
Argyropoulos et al. Forecasting economic activity from yield curve factors
JP2017534851A5 (enExample)
BR112014012003A2 (pt) sistema de controle de qualidade, método e meio legível por computador para o uso com bens de consumo, usuários e dispositivos de teste de diagnóstico biológico/ambiental
PE20180930A1 (es) Composiciones y metodos para la vigilancia activa del cancer de prostata
Maas et al. Strange nucleon form-factors
BR112016021714A2 (pt) imunoensaio e anticorpos para a detecção de cromogranina a
BR112016015537A2 (pt) métodos e kits para detectar a presença de sequência polinucleotídea da e. histolytica em amostra
ES2498790A1 (es) Procedimiento para la detección magneto-electroquímica sin lavados de un analito en una muestra
EP3315613A3 (en) Methods and kits for diagnosing or assessing the risk of cervical cancer
BR112017020539B8 (pt) Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico
HK1243953A1 (zh) 检测人dpp-4的测定法
BR112015023792A2 (pt) métodos e aparelhos para identificar perfil de anticorpo em um indivíduo ou uma fonte de material biológico